Skip to main content

Table 1 Anti-HIV and HCV mAbs in clinical development.

From: Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases

Compound Target Origin Company Indication
MAbs against viral antigens
3 mAb cocktail
C2F5, C2G12, and C4E10
Anti-Gp41, anti-glycan structure of Gp120 Human mAb Rockefeller University Therapy of HIV infection Phase I/II
P2G12 Anti-glycan structure of Gp120 Human mAb University of Surrey
European Commission
Prevention of HIV infection Phase I
KD-247 Anti-V3 loop of HIV-1 Env Humanized mAb The Chemo-Sero-Therapeutic Research Institute Therapy of HIV infection Phase I
F105 Anti-Gp120, CD4 binding site Human mAb National Institute of Allergy and Infectious Diseases (NIAID) Therapy of HIV infection Phase I
MBL-HCV1 Anti-E2 Human mAb MassBiologics Prevention of liver reinfection with HCV after transplantation Phase II
MAbs against host antigens
IBALIZUMAB Anti-CD4 receptor Humanized mAb TaiMed Biologics/Tanox Therapy of HIV infection Phase I/II
PRO-140 Anti-CCR5 receptor Humanized mAb Progenics/PDL Therapy of HIV infection Phase I/II
CCR5mAb004 Anti-CCR5 receptor Human mAb Human Genome Sciences Therapy of HIV infection Phase I
BAVITUXIMAB Anti-phosphatidyl serine. Chimeric mAb Peregrine Pharmaceuticals Therapy of HIV/HCV co-infection Phase II Therapy of chronic HCV infection co-administrated with ribavirin Phase II
Immunomodulatory mAbs
TREMELIMUMAB
CP 675,206
Anti-CTLA-4 Humanized mAb Pfizer Therapy of HIV infection Phase I (study withdrawn prior to enrollment) Therapy of advanced HCC in HCV infected patient Phase II
CT-011 Anti-PD-1 Humanized mAb CureTech Therapy of chronic HCV infection Phase I/II
BMS 936558
(MDX1106)
Anti-PD-1 Human mAb Bristol-Myers Squibb/Medarex Therapy of chronic HCV infection Phase I